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Abstract
Background: Polymorphisms of the prion protein gene (PRNP) at codons 129 and 219 play an
important role in the susceptibility to Creutzfeldt-Jakob disease (CJD), and might be associated
with other neurodegenerative disorders. Several recent reports indicate that polymorphisms
outside the coding region of PRNP modulate the expression of prion protein and are associated
with sporadic CJD, although other studies failed to show an association. These reports involved
the polymorphism PRNP 1368 which is located upstream from PRNP exon 1. In a case-controlled
protocol, we assessed the possible association between the PRNP 1368 polymorphism and either
Alzheimer's disease (AD) or vascular dementia (VaD).
Methods: To investigate whether the PRNP 1368 polymorphism is associated with the occurrence
of AD or VaD in the Korean population, we compared the genotype, allele, and haplotype
frequencies of the PRNP 1368 polymorphism in 152 AD patients and 192 VaD patients with
frequencies in 268 healthy Koreans.
Results and conclusion: Significant differences in genotype, allele and haplotype frequencies of
PRNP 1368 polymorphism were not observed between AD and normal controls. There were no
significant differences in the genotype and allele frequencies of the PRNP 1368 polymorphism
between Korean VaD patients and normal controls. However, in the haplotype analysis, haplotype
Ht5 was significantly over-represented in Korean VaD patients. This was the first genetic
association study of a polymorphism outside the coding region of PRNP in relation to AD and VaD.
Background
Alzheimer's disease (AD), the most common cause of
dementia in the aged population, is associated with pro-
gressive memory deterioration and disordered cognitive
function resulting from a loss of cholinergic transmission
and characterized neuropathologically by the presence of
neurofibrillary tangles and amyloid plaques in the brain
and clinically by gradual loss of memory. These changes
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may result from destructive processes involving the dis-
ruption of microtubule assembly and synaptic loss. Fur-
ther neuronal damage and disease progression are
consequences of this damage. Although the processes
involved in AD could be triggered by many environmen-
tal factors, genetic studies have shown that in some cases
mutations and polymorphisms of particular genes can
confer susceptibility to the degenerative process. Several
genes associated with AD have been identified, including
amyloid precursor protein gene (APP), presenilin-1 gene
(PS1), presenilin-2 gene (PS2), and the apolipoprotein E
gene (ApoE) [1]. AD and prion diseases, such as Creut-
zfeldt-Jakob disease (CJD), share a number of clinical,
pathogenetic and pathological features. A structural hall-
mark of AD is amyloid-β peptide (Aβ) aggregates in extra-
cellular amyloid deposits defined as senile plaques, while
in CJD there is an accumulation of abnormal protease-
resistant isoform (PrPres) in neurons and in extracellular
amyloid-like aggregates. Aβ-positive senile plaques in AD
brains commonly contain PrPC deposits [2-4] and inci-
dental Aβ-positive senile plaques in prion diseases such as
CJD may also be positive for PrPC [5].
Vascular dementia (VaD) is the second most common
cause of dementia after AD. VaD is a clinical syndrome
causing cognitive decline due to cerebrovascular lesions.
Risk factors for VaD are age, sex, race, hypertension, smok-
ing, diabetes mellitus, and hypercholesterolemia. How-
ever, there is no conclusive evidence for the association of
genetic polymorphisms with VaD. VaD and prion diseases
share some pathophysiological similarities, such as the
occurrence of dementia.
Prion protein contains 253 amino acids encoded by prion
protein gene (PRNP), located on chromosome 20p12.3 in
humans. PRNP plays an important role in conferring sus-
ceptibility or resistance to prion disease. A number of
mutations in the open reading frame (ORF) are linked to
the familial form of prion diseases [6,7]. Polymorphisms
at codons 129 or 219 of PRNP are susceptibility factors to
sporadic CJD [8-11]. In several European populations, an
association between the PRNP codon 129 polymorphism
and AD was reported [12-15]. In contrast to these studies,
other studies failed to detect a significant association
between this polymorphism and AD [16-18], and in Asian
populations, no association between the PRNP codons
129/219 polymorphisms and AD was reported [19].
Recently, the polymorphism (PRNP 1368) in an upstream
of PRNP exon 1 was found to be associated with sporadic
CJD in British and German populations [20,21], but this
association was not seen in Dutch and Korean popula-
tions [22,23]. This polymorphism was studied in other
diseases in addition to sporadic CJD. In a British popula-
tion, there was no association of PRNP 1368 polymor-
phism with frontotemporal lobar degeneration (FTLD)
[24]. Although PRNP 1368 polymorphism has been stud-
ied in sporadic CJD and FTLD patients, a case-controlled
association study between the PRNP 1368 polymorphism
and either AD or VaD has not been reported thus far.
In the present study, the purpose was to investigate the
genotype and allele frequency of a polymorphism outside
the coding region of PRNP  in Korean AD and VaD
patients and to determine the correlation between this
polymorphism and the incidence of AD and VaD in the
Korean population.
Methods
Subjects
Analysis included 152 Korean patients with AD (51 male
and 101 female; mean age at disease onset 73.48 ± 8.00
years), which were diagnosed according to the National
Institute of Neurological and Communicative Disorders
and Stroke-Alzheimer's Disease and Related Disorders Asso-
ciation (NINCDS-ADRDA) criteria [25] with minor modifi-
cation specifying the gradual onset and progression of
memory loss with a duration of at least 12 months. None of
these patients reported family history of AD. All AD patients
were gathered from Chunchon, South Korea and were
examined in the Department of Neurology, Chunchon
Sacred Heart Hospital. General medical and neurological
examinations, neuropsychological testing, and computed
topography scans were performed to exclude other forms of
dementia. Blood samples were collected from 152 AD
patients between May 2000 and June 2005. One hundred
ninety two Korean patients with VaD (100 male and 92
female; mean age: 71.95 ± 8.92 years) were diagnosed
according to the Diagnostic and Statistical Manual of Men-
tal Disorders, Fourth Edition (DSM-IV) [26] and National
Institute of Neurological Disorders and Stroke-Association
Internationale pour la Recherche et l'Enseignement en Neu-
rosciences (NINDS-AIREN) criteria [27] after clinical exam-
ination and neuropsychological testing, including mini-
mental state examination (MMSE). VaD patients were gath-
ered from Anyang, South Korea and were examined in the
Department of Neurology, Hallym University Hospital.
Blood samples were collected from 192 VaD patients
between May 2000 and June 2008. The control subjects
were 268 unrelated individuals (118 male and 150 female;
mean age 71.17 ± 8.68 years) matched for age and ethnic
background to AD patients and VaD patients (Table 1). All
control subjects were volunteers recruited from routine
health checkups at the Chunchon Sacred Heart Hospital.
None of them presented symptoms of dementia or any
movement disorders. Absence of dementia was determined
by considering past history and Korean MMSE criterion
(score of >24). Blood samples were collected from 268
healthy Korean volunteers between May 2000 and June
2005. The study was approved by the Ethical Committee of
Chunchon Sacred Heart Hospital and an informed consent
was given by all subjects or their caregivers. All blood sam-
ples were frozen at -70°C prior to analysis.BMC Medical Genetics 2009, 10:32 http://www.biomedcentral.com/1471-2350/10/32
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Genotyping
Genomic DNA was extracted from 200 μl blood using the
QIAamp DNA blood mini kit (Qiagen, USA) following
the supplier's instructions. Polymerase chain reaction
(PCR) was performed with J-1 (GAGAAAACCTTGCGT-
CAGCA) and J-2 (AAGGTGCAGAAAAGATGGGC) prim-
ers. These primers were designed to amplify a 586 bp
product in an upstream region of PRNP exon 1. The PCR
reagents contained 50 pmole of each primer, 5 μl of 10 ×
Taq DNA polymerase buffer, 1.5 mM MgCl2, 0.2 mM of
each dNTP mixtures, and 2.5 units of Taq DNA polymer-
ase (Promega, USA). The PCR conditions were 94°C for 2
min to denature, and 35 cycles of 94°C for 45 sec, 56°C
for 45 sec, and 72°C for 1 min 30 sec, and then 1 cycle of
72°C for 10 min to extend the reaction. The Perkin-Elmer
Cetus DNA thermal cycler (Pekin-Elmer, USA) was used.
Restriction cleavage sites were searched using Webcutter,
ver. 2.0 (Carolina Biological Supply Co., USA). A 20 μl
aliquot of purified PCR mixture was digested at 37°C for
1 h with 5 units of Pvu II (Invitrogen, USA). Restriction
products were separated on a 1.5% agarose gel and visual-
ized with ethidium bromide staining under UV light. The
purification of PCR products for sequencing was done
using a QIAquick gel extraction kit (Qiagen, USA). The
PCR products were directly sequenced on an ABI 377
automatic sequencer using a Taq dideoxy terminator cycle
sequencing kit (ABI, USA) and the same primers as indi-
cated earlier in the standard conditions.
Statistical analyses
A χ2 test was used to determine whether the PRNP 1368
polymorphism was in Hardy-Weinberg equilibrium
(HWE) in the Korean population. Odds ratios (OR) with
95% confidence interval (CI) and P-values were calculated
by using the codominant model, controlling for age and
sex as covariates. Differences in age of populations were
analyzed using Student's t-test, and sex differences by
using  χ2  test. Haplotypes and their frequencies were
inferred using the algorithm developed by Stephens et al.
[28]. Fisher's exact test was used to analyze differences in
haplotype frequency between the normal population and
patients with AD and VaD. The statistical powers were cal-
culated using Statistical Power Calculator http://www.dss
research.com/toolkit/spcalc/power_p2.asp.
Results
The genotype frequencies at PRNP 1368 were in HWE in
Korean control group (P = 0.742) and AD group (P =
0.226), not in VaD group (P = 0.025) (data not shown).
To examine a correlation between the PRNP 1368 poly-
morphism and susceptibility of AD in Koreans, we exam-
ined the genotype and allele frequencies of this
polymorphism in 152 Korean AD patients and in 268
healthy controls. No significant difference between
Korean AD patients and controls was found in genotype
or allele frequency of the PRNP  1368 polymorphism
(Table 2). This result suggests that the PRNP 1368 poly-
morphism does not increase susceptibility to AD. When
our data set was stratified by gender, there was no signifi-
cant association between this polymorphism and AD
(data not shown).
We also investigated the genotype and allele frequencies
of PRNP 1368 in 192 Korean VaD patients to determine
whether this polymorphism correlated with VaD. There
were no significant differences in genotype and allele fre-
quencies between VaD patients and controls (Table 2). In
addition, analysis of the haplotype frequency was per-
formed in AD patients, VaD patients and controls. Six
haplotypes of the 3 PRNP  polymorphisms were con-
structed in Koreans. One (ht 5) of these six haplotypes was
significantly over-represented in Korean VaD patients
(Table 3).
Discussion
In this study, we failed to detect a significant association
between the PRNP 1368 polymorphism and the occur-
rence of either AD or VaD in the Korean population.
There is the possibility that the PRNP  1368 polymor-
phism is not functional with regard to affecting the level
of PrPC. Another possibility is that a false negative result
was obtained due to statistical powers. Data for AD and
VaD patients showed a statistical power of 19.1% and
11.2%, respectively, at the Type I error rate of 0.05 com-
pared with healthy controls. The statistical powers aren't
high enough for ensuring that the PRNP 1368 polymor-
phism is not relevant to prion replication. However, in the
haplotype analysis among 3 PRNP polymorphisms, hap-
Table 1: Characteristics of AD and VaD patients and controls
Control AD P valuea VaD P valuea
Number of subjects 268 152 192
Gender
Male, n (%) 118 (44.0%) 51 (33.55%) 0.014 100 (52.1%) 0.090
Female, n (%) 150 (56.0%) 101 (66.45%) 92 (47.9%)
Mean age at disease onset (years ± SD) - 73.48 ± 8.00 0.006 71.95 ± 8.92 0.348
Mean age at blood collection (years ± SD) 71.17 ± 8.68 - -
aBased on the difference between controls and AD or VaD patientsBMC Medical Genetics 2009, 10:32 http://www.biomedcentral.com/1471-2350/10/32
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lotype ht5 was the only haplotype significantly associated
with VaD (p = 0.013) (Table 3) and the genotype fre-
quency of PRNP 1368 polymorphism in VaD patients was
not in HWE. These results suggested some interaction
among 3 PRNP polymorphisms in the determination of
VaD risk and were needed for further evaluation of the
association of PRNP 1368 polymorphism with VaD in
other ethnic groups.
Although the exact function of the prion protein is not
fully understood, it might be involved in the development
and intensity of oxidative stress and, thereby, contribute
to neurodegeneration. Thus, polymorphisms in the cod-
ing region of PRNP might influence other neurodegenera-
tive disorders in addition to prion diseases. Many studies
on a correlation between the PRNP codon 129 and AD in
various populations have yielded contradictory results
[12-19]. This controversial result may be due to the differ-
ent sample size of the population analyzed, to a difference
in frequency of PRNP genotypes between different ethnic
groups [29], or even to a difference in age of onset. In our
previous studies, we failed to detect a significant associa-
tion between PRNP  polymorphism at codons 129/219
and the risk for AD or VaD in the Korean population
[30,31].
Recently, there has been growing concern about several
polymorphisms outside the ORF of PRNP, as there is evi-
dence that levels of PRNP expression influence incubation
time and the susceptibility to prion diseases. Polymor-
phisms in the PRNP promoter region may be associated
with increased susceptibility of prion diseases in cattle
and mice [32-34]. These PRNP promoter polymorphisms
influence the PRNP gene expression level [35]. Overex-
pression of PRNP in transgenic mice led to a decrease in
incubation time, whereas PRNP  knockout mice were
resistant to prion disease after infection [36,37]. There-
fore, we suggest that the polymorphism of PRNP 1368,
located in the promoter region, may influence the expres-
sion of the PRNP gene; the promoter polymorphisms of
PRNP might also be associated with other neurodegener-
ative diseases. In previous studies, several polymorphisms
were identified in intronic and upstream regions of
human  PRNP. The single nucleotide polymorphism
(SNP) at position -101 (PRNP 12533) within the regula-
tory region of PRNP was associated with sporadic CJD in
the British population [38], but not in samples derived
from Dutch and German populations [20,39].
Even though these results did not show a relationship
between PRNP 1368 and AD or VaD, it would be useful to
Table 2: Genotype and allele frequencies of the PRNP 1368 polymorphism in the normal population, AD patients, and VaD patients
Control
(n = 268)
AD
(n = 152)
VaD
(n = 192)
AD vs Control VaD vs control
ORa 95% CIb P value OR 95%
CI
P value
Genotype frequency
CC 103 (38.4) 56 (36.8) 84 (43.8) - - - - - -
CT 124 (46.3) 67 (44.1) 74 (38.5) 0.994 0.640 – 1.544 0.978 0.732 0.487 – 1.100 0.133
TT 41 (15.3) 29 (20.1) 34 (17.7) 1.301 0.731 – 2.315 0.371 1.017 0.594 – 1.742 0.952
Allele frequency
C 330 (61.6) 179 (58.9) 242 (63.0) - - - - - -
T 206 (38.4) 125 (41.1) 142 (37.0) 1.119 0.839 – 1.491 0.444 0.940 0.717 – 1.232 0.654
Figures in parentheses are percentages
aOdds ratio
bConfidence interval
Table 3: Haplotype frequency of three PRNP polymorphisms in the normal population, AD patients, and VaD patients
Haplotypes 1368 Codon 129 Codon 219 Frequency P value
AD VaD Control AD vs Control VaD vs Control AD vs VaD
ht1 C A G 0.5592 0.5622 0.5951 - - -
ht2 T A G 0.3618 0.3623 0.3450 0.479 0.451 0.996
ht3 T A A 0.0263 0.0142 0.0292 0.990 0.167 0.215
ht4 T G G 0.0197 0.0037 0.0115 0.280 0.252 0.050
ht5 C A A 0.0164 0.0352 0.0109 0.333 0.013 0.226
ht6 C G G 0.0066 0.0224 0.0083 1.0 0.078 0.197BMC Medical Genetics 2009, 10:32 http://www.biomedcentral.com/1471-2350/10/32
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assess associations between AD/VaD and other PRNP pol-
ymorphisms in the promoter region, including the PRNP
12533 polymorphism.
Conclusion
PRNP 1368 polymorphism was not significantly associ-
ated with incidence of sporadic AD and VaD in Koreans.
However, in the haplotype analysis among 3 PRNP poly-
morphisms, we observed a significant association
between haplotype ht5 and VaD. Our report is the first
association study of a polymorphism outside the coding
region of PRNP with AD and VaD.
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